Top Page
GNI Group
(2160)
GNI Group (2160) vs. iShares MSCI Japan ETF (EWJ)
GNI Group Business Overview & Revenue Model
GNI Group Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.13B | 23.61B | 26.01B | 17.42B | 12.69B | 9.77B |
| Gross Profit | 17.30B | 18.04B | 22.43B | 14.74B | 11.09B | 8.23B |
| EBITDA | 105.29M | 2.39B | 14.49B | 2.16B | 2.14B | 2.19B |
| Net Income | -267.85M | 977.66M | 8.09B | 388.82M | 1.07B | 1.26B |
Balance Sheet | ||||||
| Total Assets | 67.72B | 71.94B | 62.39B | 33.91B | 30.30B | 23.22B |
| Cash, Cash Equivalents and Short-Term Investments | 10.52B | 12.93B | 23.15B | 11.25B | 14.36B | 10.34B |
| Total Debt | 4.86B | 7.21B | 3.70B | 537.36M | 1.13B | 1.75B |
| Total Liabilities | 29.41B | 32.23B | 26.34B | 14.10B | 11.03B | 10.45B |
| Stockholders Equity | 35.27B | 36.45B | 33.79B | 20.97B | 18.86B | 11.00B |
Cash Flow | ||||||
| Free Cash Flow | -3.03B | -3.69B | 4.47B | -1.55B | -142.13M | 1.02B |
| Operating Cash Flow | -2.63B | -3.16B | 6.55B | 393.32M | 552.27M | 1.38B |
| Investing Cash Flow | -918.42M | -10.36B | -6.84B | -4.12B | -260.64M | 570.21M |
| Financing Cash Flow | -999.41M | 694.16M | 10.69B | -646.33M | 2.85B | 801.12M |
GNI Group Technical Analysis
GNI Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ¥111.14B | 192.62 | ― | 1.87% | 6.98% | 406.15% | |
| ― | $214.60B | 14.74 | -9.08% | ― | -65.56% | -123.22% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $193.76B | ― | -252.15% | ― | ― | -58.12% | |
| ― | €131.51B | 108.76 | -0.47% | ― | 2.04% | -102.04% | |
| ― | $87.69B | ― | -5.01% | ― | 33.71% | 68.32% | |
| ― | ¥56.80B | ― | ― | ― | -78.54% | 10.23% |
GNI Group Corporate Events
GNI Group Ltd. announced that its subsidiary, Gyre Therapeutics, has completed subject enrollment for a Phase 3 clinical trial of Pirfenidone Capsule, aimed at treating pneumoconiosis. This trial, conducted across 18 centers in China, evaluates the drug’s efficacy and safety over 52 weeks. The completion of enrollment marks a significant step in the development of treatments for this chronic lung disease, although the financial impact on GNI Group’s current fiscal year is expected to be minimal.
The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2551.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
GNI Group Ltd. announced the completion of subject enrollment for the Phase 1 clinical trial of CG001419, a novel non-opioid pain product candidate developed by its subsidiary Cullgen. This trial marks a significant step in offering a new class of pain signal inhibitors that could provide safer and more effective treatment options for acute and chronic pain, with plans to advance to Phase 2 trials by early next year. The financial impact on the company’s current fiscal year is expected to be minimal.
The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2551.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
GNI Group Ltd. has conducted an overseas equity offering to raise growth capital, aiming to enhance its global market presence and attract international institutional investors. This strategic move is part of the company’s flexible capital strategy to support long-term shareholder value and accelerate growth. The funds will be used to explore M&A opportunities and further develop its drug portfolio, including the F351 product for liver fibrosis, while maintaining a balanced approach to future financing options.
The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2551.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
GNI Group Ltd. has appointed Takuya Kaneko as Executive Officer and Chief Strategy Officer, effective August 28, 2025, to strengthen its global management structure and pursue sustainable growth. Kaneko’s extensive experience in investment banking and biotechnology is expected to aid the company in expanding its revenue base in Japan and advancing its global healthcare strategies, benefiting stakeholders and contributing to the healthcare industry’s advancement.
The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2735.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
GNI Group Ltd. reported its consolidated financial results for the second quarter of fiscal year 2025, showing a 4.4% increase in revenue compared to the previous year. However, the company experienced a decline in operating income and pre-tax profit, resulting in a net loss for the period. This financial performance may impact the company’s market positioning and stakeholder confidence as it navigates challenges in the pharmaceutical industry.
The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
GNI Group Ltd. announced that its subsidiary, Gyre Therapeutics, has acquired additional shares in Gyre Pharmaceuticals, increasing its equity interest to 69.72%. This strategic move aims to minimize profit outflows to minority shareholders and enhance the Group’s corporate value, particularly as Gyre Pharmaceuticals is set to handle the entire value chain for a new liver fibrosis drug candidate. The acquisition is expected to positively impact the Group’s financial results, although the exact effect is still under review.
The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.